Abstract
Chronic systemic inflammatory response is proposed as an underlying mechanism for development of cancer cachexia. We conducted a prospective study to examine changes in inflammatory biomarkers during the disease course and the relationship between inflammatory biomarkers and cachexia in patients with inoperable pancreatic cancer. Twenty patients, median (range) age 67.5 (35–79) years, 5 females, were followed for median 5.5 (1–12) months. Cachexia was diagnosed according to the 2011 consensus-based classification system (weight loss >5 % past six months, BMI < 20 kg/m2 and weight loss >2 %, or sarcopenia) and the modified Glasgow Prognostic score (mGPS) that combines CRP and albumin levels. Inflammatory biomarkers were measured by enzyme immunoassays. The patients had increased levels of most inflammatory biomarkers, albeit not all statistically significant, both at study entry and close to death, indicating ongoing inflammation. According to the consensus-based classification system, eleven (55 %) patients were classified as cachectic upon inclusion. They did not differ from non-cachectic patients with regard to inflammatory biomarkers or energy intake. According to the mGPS, seven (35 %) were defined as cachectic and had a higher IL-6 (p < 0.001) than the non-cachectic patients. They also had a slightly, but insignificantly longer survival than non-cachectic patients (p = 0.08). The mGPS should be considered as an additional framework for identification of cancer cachexia.
Similar content being viewed by others
References
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96. doi:10.3322/CA.2007.0010.
Kneuertz PJ, Cunningham SC, Cameron JL, Torrez S, Tapazoglou N, Herman JM, et al. Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience. J Gastrointest Surg. 2011;15(11):1917–27. doi:10.1007/s11605-011-1665-9.
Wigmore SJ, Plester CE, Richardson RA, Fearon KC. Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer. 1997;75(1):106–9.
Tisdale MJ. Cancer cachexia. Curr Opin Gastroenterol. 2010;26(2):146–51. doi:10.1097/MOG.0b013e3283347e77.
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95. doi:10.1016/S1470-2045(10)70218-7.
Hopkinson JB, Wright DN, McDonald JW, Corner JL. The prevalence of concern about weight loss and change in eating habits in people with advanced cancer. J Pain Symptom Manage. 2006;32(4):322–31. doi:10.1016/j.jpainsymman.2006.05.012.
Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793–9. doi:10.1016/j.clnu.2008.06.013.
Douglas E, McMillan DC. Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score. Cancer Treat Rev. 2014;40(6):685–91.
Blum D, Omlin A, Baracos VE, Solheim TS, Tan BH, Stone P, et al. Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit Rev Oncol Hematol. 2011;80(1):114–44. doi:10.1016/j.critrevonc.2010.10.004.
Gulen ST, Karadag F, Karul AB, Kilicarslan N, Ceylan E, Kuman NK, et al. Adipokines and systemic inflammation in weight-losing lung cancer patients. Lung. 2012;190(3):327–32.
Roxburgh CSD, McMillan DC. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer. 2014;110(6):1409–12. doi:10.1038/bjc.2014.90.
Cesari M, Penninx BWJH, Pahor M, Lauretani F, Corsi AM, Williams GR, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol Ser A Biol Sci Med Sci. 2004;59(3):M242–8. doi:10.1093/gerona/59.3.M242.
Tuca A, Jimenez-Fonseca P, Gascon P. Clinical evaluation and optimal management of cancer cachexia. Crit Rev Oncol Hematol. 2013;88(3):625–36. doi:10.1016/j.critrevonc.2013.07.015.
Martignoni ME, Kunze P, Hildebrandt W, Kunzli B, Berberat P, Giese T, et al. Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Cancer Res. 2005;11(16):5802–8. doi:10.1158/1078-0432.CCR-05-0185.
Sabat R, Grütz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010;21(5):331–44.
Laird BJ, Kaasa S, McMillan DC, Fallon MT, Hjermstad MJ, Fayers P, et al. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clin Cancer Res. 2013;19(19):5456–64.
Klepstad P, Kaasa S. The importance and pitfalls of correlational science in palliative care research. Curr Opin Support Palliat Care. 2012;6(4):508–13. doi:10.1097/SPC.0b013e32835a0c70.
Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15(8):2920–6. doi:10.1158/1078-0432.CCR-08-2242.
Wesseltoft-Rao N, Holven KB, Telle-Hansen VH, Narverud I, Iversen PO, Hjermstad MJ, et al. Measurements of body fat is associated with markers of inflammation, insulin resistance and lipid levels in both overweight and in lean, healthy subjects. e-SPEN Journal. 2012;7(6):e234–40. doi:10.1016/j.clnme.2012.10.002.
Lillegaard IT, Andersen LF. Validation of a pre-coded food diary with energy expenditure, comparison of under-reporters v. acceptable reporters. Br J Nutr. 2005;94(6):998–1003.
Blaker B, Aarsland M. Mål og vekt for matvarer. Oslo: Landsforeningen for Kosthold & Helse; 1989. p. 6–41.
Thomas B. Manual of dietetic practice. 2nd ed. Oxford: Blacwell; 1994.
van der Meij BS, Schoonbeek CP, Smit EF, Muscaritoli M, van Leeuwen PA, Langius JA. Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworks. Br J Nutr. 2013;109(12):2231–9. doi:10.1017/S0007114512004527.
Engels JM, Diehr P. Imputation of missing longitudinal data: a comparison of methods. J Clin Epidemiol. 2003;56(10):968–76. doi:10.1016/S0895-4356(03)00170-7.
Seelaender M, Batista M Jr, Lira F, Silverio R, Rossi-Fanelli F. Inflammation in cancer cachexia: to resolve or not to resolve (is that the question?). Clin Nutr. 2012;31(4):562–6. doi:10.1016/j.clnu.2012.01.011.
Bilir C, Engin H, Can M, Temi Y, Demirtas D. The prognostic role of inflammation and hormones in patients with metastatic cancer with cachexia. Med Oncol. 2015;32(3):1–6. doi:10.1007/s12032-015-0497-y.
Garcia JM, Garcia-Touza M, Hijazi RA, Taffet G, Epner D, Mann D, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab. 2005;90(5):2920–6. doi:10.1210/jc.2004-1788.
Kemik O, Sumer A, Kemik AS, Hasirci I, Purisa S, Dulger AC, et al. The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer. World J Surg Oncol. 2010;8:85. doi:10.1186/1477-7819-8-85.
Khalid U, Spiro A, Baldwin C, Sharma B, McGough C, Norman AR, et al. Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation. Support Care Cancer. 2006;15(1):39–46. doi:10.1007/s00520-006-0091-0.
Bye A, Jordhoy MS, Skjegstad G, Ledsaak O, Iversen PO, Hjermstad MJ. Symptoms in advanced pancreatic cancer are of importance for energy intake. Support Care Cancer. 2013;21(1):219–27. doi:10.1007/s00520-012-1514-8.
Yavuzsen T, Walsh D, Davis MP, Kirkova J, Jin T, LeGrand S, et al. Components of the anorexia-cachexia syndrome: gastrointestinal symptom correlates of cancer anorexia. Support Care Cancer. 2009;17(12):1531–41. doi:10.1007/s00520-009-0623-5.
Wesseltoft-Rao N, Hjermstad MJ, Ikdahl T, Dajani O, Ulven SM, Iversen PO, et al. Comparing two classifications of cancer cachexia and their association with survival in patients with unresected pancreatic cancer. Nutr Cancer. 2015;67(3):472–80.
Kyrana E, Briggs S, Dhawan A. Molecular mechanisms of cachexia in chronic disease. Expert Rev Endocrinol Metab. 2012;7(1):73–90. doi:10.1586/eem.11.87.
Gordon JN, Green SR, Goggin PM. Cancer cachexia. Q J Med. 2005;98:779–88. doi:10.1093/qjmed/hci127.
Holmer R, Goumas FA, Waetzig GH, Rose-John S, Kalthoff H. Interleukin-6: a villain in the drama of pancreatic cancer development and progression. Hepatobiliary Pancreat Dis Int. 2014;13(4):371–80. doi:10.1016/S1499-3872(14)60259-9.
Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma. Cancer. 2004;101(12):2727–36. doi:10.1002/cncr.20672.
Scheede-Bergdahl C, Watt HL, Trutschnigg B, Kilgour RD, Haggarty A, Lucar E, et al. Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia? Clin Nutr. 2012;31(1):85–8. doi:10.1016/j.clnu.2011.07.010.
Dalamaga M, Migdalis I, Fargnoli JL, Papadavid E, Bloom E, Mitsiades N, et al. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control. 2009;20(5):625–33. doi:10.2307/40272028.
Wolf I, Sadetzki S, Kanety H, Kundel Y, Pariente C, Epstein N, et al. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer. 2006;106(4):966–73. doi:10.1002/cncr.21690.
Creutzberg EC, Wouters EFM, Vanderhoven-Augustin IML, Dentener MA, Schols AMWJ. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162(4):1239–45. doi:10.1164/ajrccm.162.4.9912016.
Li M-D. Leptin and beyond: an odyssey to the central control of body weight. Yale J Biol Med. 2011;84(1):1–7.
Schautz B, Later W, Heller M, Peters A, Müller MJ, Bosy-Westphal A. Impact of age on leptin and adiponectin independent of adiposity. Br J Nutr. 2012;108(02):363–70. doi:10.1017/S0007114511005605.
Costelli P, Muscaritoli M, Bossola M, Penna F, Reffo P, Bonetto A, et al. IGF-1 is downregulated in experimental cancer cachexia. Am J Physiol Regul Integr Comp Physiol. 2006;291(3):R674–R83. doi:10.1152/ajpregu.00104.2006.
Fouladiun M, Korner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care–correlations with food intake, metabolism, exercise capacity, and hormones. Cancer. 2005;103(10):2189–98. doi:10.1002/cncr.21013.
Hall DT, Ma JF, Di Marco S, Gallouzi I-E. Inducible nitric oxide synthase (iNOS) in muscle wasting syndrome, sarcopenia, and cachexia. Aging (Albany NY). 2011;3(8):702–15.
Vlachostergios PJ, Gioulbasanis I, Kamposioras K, Georgoulias P, Baracos VE, Ghosh S, et al. Baseline insulin-like growth factor-I plasma levels, systemic inflammation, weight loss and clinical outcome in metastatic non-small cell lung cancer patients. Oncology. 2011;81(2):113–8. doi:10.1159/000331685.
Thoresen L, Fjeldstad I, Krogstad K, Kaasa S, Falkmer UG. Nutritional status of patients with advanced cancer: the value of using the subjective global assessment of nutritional status as a screening tool. Palliat Med. 2002;16(1):33–42.
Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363(9414):1049–57. doi:10.1016/S0140-6736(04)15841-8.
Labori KJ, Hjermstad MJ, Wester T, Buanes T, Loge JH. Symptom profiles and palliative care in advanced pancreatic cancer: a prospective study. Support Care Cancer. 2006;14(11):1126–33. doi:10.1007/s00520-006-0067-0.
Acknowledgments
The entire data collection was carried out at the Departments of Surgery, Oncology and Palliative Care at Oslo University Hospital. Appreciation is expressed to the staff of the study and to patients who participated.
Funding
This study was funded by Oslo and Akershus University College of Applied Sciences and Hole’s trust fund.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Bye, A., Wesseltoft-Rao, N., Iversen, P.O. et al. Alterations in inflammatory biomarkers and energy intake in cancer cachexia: a prospective study in patients with inoperable pancreatic cancer. Med Oncol 33, 54 (2016). https://doi.org/10.1007/s12032-016-0768-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-016-0768-2